Brief
UCLA AI system MAESTRO proposes new drug combos to beat prostate‑cancer resistance
The MAESTRO platform uses large‑language models to scan biomedical literature and propose combinations that could boost the effect of enzalutamide.
By Felo News Desk · Published
Researchers at the University of California, Los Angeles announced on 22 October that their new artificial‑intelligence system, MAESTRO, can identify promising drug combinations to counter treatment‑resistance in prostate cancer, according to a university press release reported by the Independent.
What happened
The team evaluated thousands of naturally occurring compounds with MAESTRO – short for Mechanistic Augmentation and Ensemble Selection for Therapeutic Ranking Optimization – and highlighted several agents that might enhance the activity of enzalutamide, an advanced prostate‑cancer medication developed at UCLA. The platform ranks candidates, provides mechanistic explanations and narrows the list for laboratory testing.
What the report adds
The Independent notes that MAESTRO relies on large‑language models to ingest existing scientific knowledge about drug mechanisms and the biological pathways cancer cells use to survive treatment. By integrating this knowledge, the system can propose combinations with a clear biological rationale, potentially accelerating the discovery process compared with traditional brute‑force screening or hypothesis‑driven literature reviews.
What was said
"Developing drug combinations currently relies on either brute‑force screening or researchers hypothesizing potential candidates based on existing literature," said Neil Lin, associate professor of mechanical and aerospace engineering and bioengineering at UCLA and senior author of the study, as quoted by the Independent.
How it came about
Prostate cancer often becomes resistant to androgen‑receptor blockers like enzalutamide because malignant cells activate alternative signalling routes. Identifying effective pairings among thousands of possible compounds has been a major challenge. MAESTRO was created to address this gap by using AI to map complex pathway interactions and suggest biologically plausible combos for experimental validation.
Key facts
- UCLA researchers unveiled an AI platform called MAESTRO to rank drug combinations for prostate cancer. (independent.co.uk)
- MAESTRO evaluated thousands of naturally occurring compounds and highlighted several that could boost enzalutamide. (independent.co.uk)
- The system uses large‑language models to process existing biomedical literature and generate mechanistic explanations. (independent.co.uk)
- Neil Lin, associate professor at UCLA, is the senior author of the study. (independent.co.uk)
Sources
- [1] independent.co.uk — originally reported as “Scientists stunned as new AI unlocks game-changing cancer treatment”
